rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SPRB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Citizens reiterates Spruce Biosciences stock rating ahead of BLA filing
      Nov 12Investing.comSPRB
      Spruce Biosciences at Guggenheim healthcare conference: FDA path in focus
      Nov 10Investing.comSPRB
      Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
      Nov 9Yahoo FinanceSPRB
      Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences
      Nov 9Yahoo FinanceSPRB
      Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
      Oct 15Yahoo FinanceSPRB
      Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
      Oct 8Yahoo FinanceSPRB
      B.Riley reiterates Buy on Spruce Biosciences stock, $160 target
      Oct 5Investing.comRILYRILYGRILYLRILYNRILYTRILYZSPRB
      Citizens reiterates Spruce Biosciences stock rating on therapy lead
      Sep 24Investing.comSPRB
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailSPRB
      Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target

      Spruce Biosciences (SPRB) has an average rating of buy and mean price target of $148, according to a

      Sep 18Yahoo FinanceSPRB
      Citizens reiterates Spruce Biosciences stock rating on gene therapy approval
      Sep 18Investing.comSPRB
      Spruce Biosciences at H.C. Wainwright: BLA path comes into focus
      Sep 17Investing.comSPRB
      Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      SOUTH SAN FRANCISCO, Calif., September 08, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.

      Sep 8Yahoo FinanceSPRB
      Spruce Biosciences stock gains after analyst backs regulatory progress

      Spruce Biosciences (NASDAQ:SPRB) stock advanced 4. 1% in pre-market trading to $64 after H.

      Aug 27Yahoo FinanceSPRB
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Tipranks Press Release.

      Aug 27The Globe and MailPDSBSPRB
      Why is Spruce Biosciences stock gaining 4% today?
      Aug 27Investing.comSPRB
      H.C. Wainwright reiterates Spruce Biosciences stock rating on BLA progress
      Aug 26Investing.comSPRB
      Spruce Biosciences Announces Launch of MPS3BStudy.com

      SOUTH SAN FRANCISCO, Calif., August 26, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the launch of MPS3BStudy.com, a dedicated online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The website enables families and caregivers to learn about, and register their interest in, th

      Aug 26Yahoo FinanceSPRB
      Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

      SOUTH SAN FRANCISCO, Calif., August 24, 2026--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has completed two pre-BLA meetings with the U.S. Food and Drug Administration (FDA) that support the company's plan to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfi

      Aug 24Yahoo FinanceSPRB

      This is the newest page. Registered accounts read further back.